- George Yu, Cyto Wave Technologies
- Scott Gill, ISTO Technologies
- Idrasil, C3 International
- Martin Leblanc, Caprion
- Jeffrey Bacha, Del Mar
- Chris Jones, Glysure
- Vijay Aggarwal, The Channel Group
- Aftab Jamil, BDO
- Jack Young, Qualcomm Ventures
- Immune Pharmaceuticals and Epicept Corporation
- DARA BioSciences, Pt. II
- Intellicell BioSciences
- DARA Biosciences Pt. I
June 14 2013
The effectiveness of Genentech and Roche’s (RHHBY.OB) glioblastoma multiforme (GBM) treatment, Avastin, has recently been challenged raising concerns from physicians and patients alike that a huge void in patient care can develop if the FDA decides to revoke Avastin’s approval for treating GBM.
June 6 2013
Or, How I Learned to Stop Worrying and Love Computational Biology.
June 5 2013
On May 29th, 2013, GlaxoSmithKline (GSK) announced the acquisition of Okairos in an all-cash deal worth $325 million US. The Okairos acquisition helps complement the pharma giant’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines.
June 4 2013
During an interview with OneMedPlace, President and Chairman of NanoViricides (NNVC) Anil Diwan summed up the influenza treatment market in just a few words: It is like trying to hit a moving target.
Partners & Sponsors